Estramustine phosphate therapy in carcinoma of the prostate.
Estramustine phosphate, a nor nitrogen mustard derivative of estradiol 17-beta-phosphate, was introduced in the treatment of prostatic carcinoma in 1966. Until March 1975, 466 patients have been reported on this treatment in open clinical trials: 82% of the patients were in stage IV. In 402 patients, nonresponsive to previous estrogen therapy, signigicant improvement occurred in 55%. In 64 previously untreated patients there was a favourable response in 83%. Side-effects were mainly bone marrow suppression. liver disturbance, thrombophlebitis following intravenous injection, and gastrointestinal troubles, mainly following oral administration. A prospective, randomized study comparing oral estramustine phosphate and conventional estrogen therapy in carcinoma of the prostate is in progress.
D000284:Administration, Oral; D001853:Bone Marrow / Q000187:drug effects; D004961:Estramustine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D007275:Injections, Intravenous; D008099:Liver / Q000187:drug effects; D008297:Male; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use*; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D013924:Thrombophlebitis / Q000139:chemically induced
D009588:Nitrogen Mustard Compounds; D004961:Estramustine